Spots Global Cancer Trial Database for Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)
Official Title: Phase I Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)
Study ID: NCT00183742
Interventions
Study Description
Brief Summary: This study is for patients with advanced cancer that has failed treatment with conventional therapy or for which no standard treatment exists. The purpose of this study is to determine the highest dose that can be given of 2 chemotherapy drugs, docetaxel (also called Taxotere) and liposomal doxorubicin (also called Doxil), when given together and to determine the side effects of this combination. Both Taxotere and Doxil are chemotherapy drugs that can decrease the size of several different tumors. Taxotere is approved by the Food and Drug Administration (FDA) for the treatment of breast and lung cancers, and Doxil is approved for the treatment of ovarian cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
U.S.C./Norris Comprehensive Cancer Center, Los Angeles, California, United States
Contact Details
Name: Syma Iqbal, M.D.
Affiliation: U.S.C./Norris Comprehensive Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
